Back to Agenda
[Session 3] Abstract Session 1
Session Chair(s)
Naoki Furuyama, DVM, PHD
Medical Information & Communication, Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Japan
Yuji Kumagai, MD, PHD
Professor, Kitasato Clinical Research Center, Kitasato University Hospital, Japan
Speaker(s)
Robert Kleiman, MD
Chief Medical Officer and Vice President, Global Cardiology, ERT, United States
Can we rely on automated ECG machine measurements for clinical trial decisions?
Georg Ferber
Statistical Consultant, Statistik Georg Ferber GmbH, Switzerland
Heart Rate Correction When the Drug Affects Heart Rate
Sanae Yasuda, PHD
Executive Director, Clinical Pharmacology Science, Deep Human Biology Learning, Eisai, Japan
Intensive QT investigation as standard practice in early clinical programs
Börje C. Darpö, MD, PHD
Chief Scientific Officer, Cardiac Safety, Clario, Sweden
Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability
Jorg Taubel, MD, FFPM
Chief Executive Officer, Richmond Pharmacology, United Kingdom
Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals
Have an account?